Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jingying Xu"'
Autor:
Xiuli Wang, Nikita Gidwaney, Adam Norris, M. Suzette Blanchard, Wen-Chung Chang, Michael C. Jensen, Samer K. Khaled, Tanya Siddiqi, Laurence J.N. Cooper, Sandra H. Thomas, Michelle Mott, Araceli Naranjo, Christine E. Brown, Stephen J. Forman, Jamie Wagner, Leslie Popplewell, Ching Lam W Wong, Brenda Chang, Stanley R. Riddell, Lihua E. Budde, Ryan Urak, Jingying Xu
Publikováno v:
Blood. 127:2980-2990
Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a mainstay of therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however, relapse rates are high. In phase 1 studies designed to improve long-term remi
Publikováno v:
Blood. 115:2709-2718
Inhibition of integrins αvβ3 and αvβ5 in human brain microvascular endothelial cells (HBMECs) by the function-blocking peptide RGDfV induces loss of spreading on vitronectin, cell detachment, and apoptosis. We demonstrate that cell detachment is
Autor:
Araceli Naranjo, ChingLam W. Wong, Wen-Chung Chang, Jamie Wagner, Stephen J. Forman, Stanley R. Riddell, Sandra H. Thomas, Brenda Chang, Christine E. Brown, Elizabeth Budde, Michael C. Jensen, Xiuli Wang, Leslie Popplewell, Samer K. Khaled, Tanya Siddiqi, Suzette Blanchard, Jingying Xu, Ryan Urak
Publikováno v:
Blood. 126:930-930
Introduction Efforts to improve the survival of non-Hodgkin lymphoma (NHL) patients with recurrent disease have focused primarily on the use of consolidative myeloablative autologous hematopoietic stem cell transplantation (HSCT). However, the major
Autor:
Huanhuan He1, Jingying Xu2, Warren, Carmen M.3, Dan Duan3,4, Lily Wu2,5, Iruela-Arispe, M. Luisa3,5,6 arispe@mcdb.ucla.edu
Publikováno v:
Blood. 10/11/2012, Vol. 120 Issue 15, p3152-3162. 11p.